Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

Phase: N/A Priority: Normal
NCT ID: NCT06486428 Org: User:
Start: 06/30/25 End: 06/30/27 Due: 06/30/28

Epidemiology of Young Lung Cancer - Survey

Phase: N/A Priority: Normal
NCT ID: NCT04640259 Org: User:
Start: 02/01/21 End: 12/30/26 Due: 12/30/27

Studying Pathways of Resistance in KRAS-driven Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05272423 Org: User:
Start: 09/08/22 End: 06/30/26 Due: 06/30/27

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

Phase: N/A Priority: Normal
NCT ID: NCT03553550 Org: User:
Start: 06/01/18 End: 11/15/20 Due: 11/15/21

Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network

Phase: N/A Priority: Normal
NCT ID: NCT01574300 Org: User:
Start: 11/30/10 End: 03/01/19 Due: 03/01/20

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

Phase: N/A Priority: Normal
NCT ID: NCT03833934 Org: User:
Start: 01/23/19 End: 06/28/24 Due: 06/28/25

ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03497624 Org: User:
Start: 04/23/18 End: 09/04/20 Due: 09/04/21

PDX Models From EGFR Mutant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03872440 Org: User:
Start: 11/14/18 End: 01/06/20 Due: 01/06/21

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04676386 Org: User:
Start: 02/01/21 End: 12/30/23 Due: 12/30/24